Arcutis Biotherapeutics (ARQT) announced that David Topper, Arcutis’ CFO is retiring from the company and Latha Vairavan, currently vice president and controller, will assume the role of CFO and join the executive team as part of a planned succession. Topper will continue to serve as CFO until the filing of the company’s first quarter 10-Q and will provide transition support through his departure on May 15.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on ARQT:
- Arcutis Biotherapeutics Positioned for Growth: Buy Rating Justified by Strategic Moves and Leadership Vision
- Positive Outlook for Arcutis Biotherapeutics Amid Patent Litigation Developments and Market Exclusivity
- Arcutis strategic valued enhanced by patent win, says H.C. Wainwright
- Strategic Advantage and Market Confidence: Arcutis Biotherapeutics’ Extended Exclusivity and Buy Rating Amidst Competitive Risks
- Positive Outlook for Arcutis Biotherapeutics Amid Legal Developments and Strategic Growth